pharmaphorum November 26, 2020
BioNTech may be deeply ensconced in the latter stages of its bid to bring a COVID-19 vaccine to market, but it’s still pushing forward on other fronts, including a partnership with InstaDeep to deploy artificial intelligence and machine learning across its business.
The two companies have been working together in this area since 2019, but BioNTech has opted to double down on the alliance with a revised agreement focusing on new immunotherapies for cancer and infectious diseases.
The headline news in the new agreement is the formation of a joint AI Innovation Lab – split between InstaDeep’s headquarters in London in the UK and BioNTech’s site in Mainz Germany – that will focus on drug discovery and design, protein engineering,...
Today's Sponsors
Today's Sponsor